FI970115A - Nukeliinihappoja sisältävä valmiste, sen valmistus ja käytöt - Google Patents

Nukeliinihappoja sisältävä valmiste, sen valmistus ja käytöt Download PDF

Info

Publication number
FI970115A
FI970115A FI970115A FI970115A FI970115A FI 970115 A FI970115 A FI 970115A FI 970115 A FI970115 A FI 970115A FI 970115 A FI970115 A FI 970115A FI 970115 A FI970115 A FI 970115A
Authority
FI
Finland
Prior art keywords
preparation
nucleic acids
pct
containing nucleic
date feb
Prior art date
Application number
FI970115A
Other languages
English (en)
Swedish (sv)
Other versions
FI970115A0 (fi
FI119738B (fi
Inventor
Jean-Paul Behr
Otmane Boussif
Barbara Demeneix
Franck Lezoualch
Mojgan Mergny
Daniel Scherman
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9465376&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI970115(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of FI970115A0 publication Critical patent/FI970115A0/fi
Publication of FI970115A publication Critical patent/FI970115A/fi
Application granted granted Critical
Publication of FI119738B publication Critical patent/FI119738B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Polyamides (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Peptides Or Proteins (AREA)
FI970115A 1994-07-13 1997-01-10 Nukleiinihapon liuosta ja kationisen polymeerin liuosta sisältävä koostumus ja käytöt FI119738B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR9408735 1994-07-13
FR9408735A FR2722506B1 (fr) 1994-07-13 1994-07-13 Composition contenant des acides nucleiques, preparation et utilisations
PCT/FR1995/000914 WO1996002655A1 (fr) 1994-07-13 1995-07-07 Composition contenant des acides nucleiques, preparation et utilisations
FR9500914 1995-07-07

Publications (3)

Publication Number Publication Date
FI970115A0 FI970115A0 (fi) 1997-01-10
FI970115A true FI970115A (fi) 1997-01-10
FI119738B FI119738B (fi) 2009-02-27

Family

ID=9465376

Family Applications (1)

Application Number Title Priority Date Filing Date
FI970115A FI119738B (fi) 1994-07-13 1997-01-10 Nukleiinihapon liuosta ja kationisen polymeerin liuosta sisältävä koostumus ja käytöt

Country Status (18)

Country Link
US (1) US6013240A (fi)
EP (1) EP0770140B1 (fi)
JP (1) JP4275728B2 (fi)
KR (1) KR100424802B1 (fi)
AT (1) ATE367448T1 (fi)
AU (1) AU2930795A (fi)
CA (1) CA2194797C (fi)
DE (1) DE69535540T9 (fi)
DK (1) DK0770140T3 (fi)
ES (1) ES2290952T3 (fi)
FI (1) FI119738B (fi)
FR (1) FR2722506B1 (fi)
IL (1) IL114566A (fi)
MX (1) MX9700270A (fi)
NO (1) NO323110B1 (fi)
PT (1) PT770140E (fi)
WO (1) WO1996002655A1 (fi)
ZA (1) ZA955849B (fi)

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2730637B1 (fr) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
IL122290A0 (en) * 1995-06-07 1998-04-05 Inex Pharmaceuticals Corp Lipid-nucleic acid complex its preparation and use
US7422902B1 (en) 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
FR2739292B1 (fr) * 1995-09-28 1997-10-31 Rhone Poulenc Rorer Sa Composition pharmaceutique utile pour la transfection d'acides nucleiques et ses utilisations
GB2324534B (en) * 1996-01-06 2000-05-10 Danbiosyst Uk Composition for delivery of nucleic acid to a cell
EP0934082B1 (de) * 1996-10-23 2002-07-17 SKW Trostberg Aktiengesellschaft Verfahren zur herstellung von biologisch aktiven polymernanopartikel-nucleinsäure-konjugaten
CA2271325A1 (en) * 1996-11-12 1998-05-22 The Regents Of The University Of California Preparation of stable formulations of lipid-nucleic acid complexes for efficient in vivo delivery
US6884430B1 (en) * 1997-02-10 2005-04-26 Aventis Pharma S.A. Formulation of stabilized cationic transfection agent(s) /nucleic acid particles
ATE466948T1 (de) * 1997-03-11 2010-05-15 Univ Minnesota Dns-basiertes transposon-system für die einführung von nucleinsäure in die dns einer zelle
US5912225A (en) 1997-04-14 1999-06-15 Johns Hopkins Univ. School Of Medicine Biodegradable poly (phosphoester-co-desaminotyrosyl L-tyrosine ester) compounds, compositions, articles and methods for making and using the same
US6524613B1 (en) 1997-04-30 2003-02-25 Regents Of The University Of Minnesota Hepatocellular chimeraplasty
DE19726186A1 (de) * 1997-06-20 1998-12-24 Boehringer Ingelheim Int Komplexe für den Transport von Nukleinsäure in höhere eukaryotische Zellen
EA003832B1 (ru) 1997-09-15 2003-10-30 Дженетик Иммьюнити, Ллс. Ген-доставочный комплекс для чрескожной доставки чужеродного генетического материала в антиген-презентирующие клетки и способы его использования
US20020022034A1 (en) * 1997-09-15 2002-02-21 Julianna Lisziewicz Therapeutic DNA vaccination
DE19743135A1 (de) 1997-09-30 1999-04-01 Hoechst Marion Roussel De Gmbh Biologisch verträgliche niedermolekular Polyethylenimine
AU4697099A (en) * 1998-06-18 2000-01-05 Johns Hopkins University School Of Medicine, The Polymers for delivery of nucleic acids
US6916490B1 (en) 1998-07-23 2005-07-12 UAB Research Center Controlled release of bioactive substances
WO2000025748A1 (fr) * 1998-11-02 2000-05-11 Terumo Kabushiki Kaisha Liposomes
US7160682B2 (en) * 1998-11-13 2007-01-09 Regents Of The University Of Minnesota Nucleic acid transfer vector for the introduction of nucleic acid into the DNA of a cell
WO2000059548A1 (en) * 1999-04-02 2000-10-12 Research Development Foundation Polyethyleneimine:dna formulations for aerosol delivery
US6770740B1 (en) 1999-07-13 2004-08-03 The Regents Of The University Of Michigan Crosslinked DNA condensate compositions and gene delivery methods
FR2797402B1 (fr) 1999-07-15 2004-03-12 Biomerieux Stelhys Utilisation d'un polypeptide pour detecter, prevenir ou traiter un etat pathologique associe a une maladie degenerative, neurologique ou autoimmune
DE19960206A1 (de) * 1999-12-14 2001-07-19 Frank Czubayko Komplexierung von RNS mit Polyethyleniminen zur deren Stabilisierung und zellulären Einschleusung
AU782912B2 (en) 1999-12-28 2005-09-08 Association Francaise Contre Les Myopathies Use of lithium (Li+) for the preparation of a composition for transfection of a polynucleotide into a cell and compositions useful in gene therapy
EP1242609A2 (en) * 1999-12-30 2002-09-25 Novartis AG Novel colloid synthetic vectors for gene therapy
FR2805271B1 (fr) * 2000-02-18 2002-04-26 Aventis Pharma Sa Procede de preparation de polyalkylenimines fonctionnalises, compositions les contenant et leurs utilisations
FR2813605B1 (fr) * 2000-09-05 2002-10-18 Aventis Pharma Sa Composes acidosensibles, leur preparation et utilisations
HUP0303379A3 (en) * 2000-09-05 2004-03-01 Gencell Sa Acid-sensitive compounds, use thereof and pharmaceutical compositions containing them
FR2814370B1 (fr) * 2000-09-22 2004-08-20 Centre Nat Rech Scient Utilisation d'un complexe acide nucleique/pei pour le ciblage de cellules souches du cerveau
DE10145134A1 (de) * 2000-10-09 2002-05-16 Bayer Ag Komplexe zur Einführung von Nukleinsäuren in Zellen
US20040048819A1 (en) * 2000-10-09 2004-03-11 Joachim Simon Complexes for transferring nucleic acids into cells
US20020091242A1 (en) 2000-10-11 2002-07-11 Michel Bessodes Acid-sensitive compounds, their preparation and uses
CA2437555A1 (en) * 2001-02-01 2002-08-08 Yiyu Zou Stabilised polymeric aerosols for pulmonary gene delivery
US6652886B2 (en) 2001-02-16 2003-11-25 Expression Genetics Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents
WO2002100435A1 (en) * 2001-06-11 2002-12-19 Centre Hospitalier Universitaire De Montreal Compositions and methods for enhancing nucleic acid transfer into cells
WO2003024481A2 (en) 2001-09-14 2003-03-27 Cytos Biotechnology Ag Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
US20030138407A1 (en) * 2001-11-02 2003-07-24 Patrick Lu Therapeutic methods for nucleic acid delivery vehicles
EP1479985B1 (en) 2002-01-17 2017-06-14 Alfa Laval Corporate AB Submerged evaporator comprising a plate heat exchanger and a cylindric casing where the plate heat exchanger is arranged
AU2003231048A1 (en) * 2002-04-22 2003-11-03 Regents Of The University Of Minnesota Transposon system and methods of use
WO2003099225A2 (en) 2002-05-24 2003-12-04 Mirus Corporation Compositions for delivering nucleic acids to cells
US7901708B2 (en) 2002-06-28 2011-03-08 Protiva Biotherapeutics, Inc. Liposomal apparatus and manufacturing methods
US20050196382A1 (en) * 2002-09-13 2005-09-08 Replicor, Inc. Antiviral oligonucleotides targeting viral families
WO2004024919A1 (en) * 2002-09-13 2004-03-25 Replicor, Inc. Non-sequence complementary antiviral oligonucleotides
ES2784011T3 (es) 2002-10-16 2020-09-21 Streck Inc Procedimiento y dispositivo para recoger y preservar las células para su análisis
US7153905B2 (en) * 2003-03-21 2006-12-26 The General Hospital Corporation Hyperbranched dendron and methods of synthesis and use thereof
EP1648519B1 (en) 2003-07-16 2014-10-08 Protiva Biotherapeutics Inc. Lipid encapsulated interfering rna
US7803397B2 (en) 2003-09-15 2010-09-28 Protiva Biotherapeutics, Inc. Polyethyleneglycol-modified lipid compounds and uses thereof
EP1737956A2 (en) * 2004-03-01 2007-01-03 Massachusetts Institute of Technology Rnai-based therapeutics for allergic rhinitis and asthma
US20050215507A1 (en) * 2004-03-04 2005-09-29 Massachusetts Institute Of Technology Therapeutic anti-cancer DNA
US20060026699A1 (en) * 2004-06-04 2006-02-02 Largaespada David A Methods and compositions for identification of genomic sequences
AU2005251403B2 (en) 2004-06-07 2011-09-01 Arbutus Biopharma Corporation Cationic lipids and methods of use
AU2005252273B2 (en) 2004-06-07 2011-04-28 Arbutus Biopharma Corporation Lipid encapsulated interfering RNA
CA2572439A1 (en) 2004-07-02 2006-01-12 Protiva Biotherapeutics, Inc. Immunostimulatory sirna molecules and uses therefor
WO2007051303A1 (en) 2005-11-02 2007-05-10 Protiva Biotherapeutics, Inc. MODIFIED siRNA MOLECULES AND USES THEREOF
US7915399B2 (en) 2006-06-09 2011-03-29 Protiva Biotherapeutics, Inc. Modified siRNA molecules and uses thereof
US20080312174A1 (en) * 2007-06-05 2008-12-18 Nitto Denko Corporation Water soluble crosslinked polymers
EP2207570A2 (en) * 2007-09-14 2010-07-21 Nitto Denko Corporation Drug carriers
EP2047858A1 (en) 2007-10-10 2009-04-15 Institut National De La Sante Et De La Recherche Medicale (Inserm) Combination products for treating cancer
EP2212425A2 (de) 2007-11-22 2010-08-04 Biontex Laboratories Gmbh Verbesserung von transfektionsergebnissen nicht-viraler genliefersysteme durch beeinflussung des angeborenen immunsystems
DE102008023913A1 (de) 2008-05-16 2009-11-19 Biontex Laboratories Gmbh Verbesserung von Transfektionsergebnissen nicht-viraler Genliefersysteme durch Beeinflussung des angeborenen Immunsystems
DE102007056488A1 (de) 2007-11-22 2009-07-23 Biontex Laboratories Gmbh Steigerung von Transfektionseffizienzen nicht-viraler Genliefersysteme durch Blockierung des angeborenen Immunsystems
DE102008016275A1 (de) 2008-03-28 2009-11-19 Biontex Laboratories Gmbh Verbesserung von Transfektionsergebnissen nicht-viraler Genliefersysteme durch Blockierung des angeborenen Immunsystems
GB0724253D0 (en) 2007-12-12 2008-01-30 Fermentas Uab Transfection reagent
AU2008342535B2 (en) 2007-12-27 2015-02-05 Arbutus Biopharma Corporation Silencing of polo-like kinase expression using interfering RNA
US7687027B2 (en) * 2008-02-27 2010-03-30 Becton, Dickinson And Company Cleaning compositions, methods and materials for reducing nucleic acid contamination
FR2928373B1 (fr) * 2008-03-05 2010-12-31 Centre Nat Rech Scient Polymere derive de la polyethylenimine lineaire pour le transfert de gene.
AU2009236219B8 (en) 2008-04-15 2015-06-25 Arbutus Biopharma Corporation Silencing of CSN5 gene expression using interfering RNA
CN102119217B (zh) 2008-04-15 2015-06-03 普洛体维生物治疗公司 用于核酸递送的新型制剂
CA2722835C (en) * 2008-05-15 2018-11-27 National Research Council Of Canada Process, vectors and engineered cell lines for enhanced large-scale transfection
CA2740000C (en) 2008-10-09 2017-12-12 Tekmira Pharmaceuticals Corporation Improved amino lipids and methods for the delivery of nucleic acids
US20100167271A1 (en) * 2008-12-30 2010-07-01 Streck, Inc. Method for screening blood using a preservative that may be in a substantially solid state form
US11634747B2 (en) * 2009-01-21 2023-04-25 Streck Llc Preservation of fetal nucleic acids in maternal plasma
DE102009006606A1 (de) 2009-01-29 2010-08-05 Philipps-Universität Marburg Nicht-virales Transfektionsmittel
WO2010096323A1 (en) 2009-02-18 2010-08-26 Streck, Inc. Preservation of cell-free nucleic acids
WO2010125544A1 (en) 2009-04-30 2010-11-04 Genetic Immunity Kft. Immunogenic nanomedicine composition and preparation and uses thereof
US9018187B2 (en) 2009-07-01 2015-04-28 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
WO2011000106A1 (en) 2009-07-01 2011-01-06 Protiva Biotherapeutics, Inc. Improved cationic lipids and methods for the delivery of therapeutic agents
CA2767127A1 (en) 2009-07-01 2011-01-06 Protiva Biotherapeutics, Inc. Novel lipid formulations for delivery of therapeutic agents to solid tumors
US9856456B2 (en) 2009-10-12 2018-01-02 Thermo Fisher Scientific Baltics Uab Delivery agent
US20130079382A1 (en) 2009-10-12 2013-03-28 Larry J. Smith Methods and Compositions for Modulating Gene Expression Using Oligonucleotide Based Drugs Administered in vivo or in vitro
GB0917792D0 (en) 2009-10-12 2009-11-25 Fermentas Uab Delivery agent
EP3103883A1 (en) 2009-11-09 2016-12-14 Streck, Inc. Stabilization of rna in and extracting from intact cells within a blood sample
US9247720B2 (en) 2010-03-24 2016-02-02 Institut National de la Santé et de la Recherche Médicale Primate model from the family cercopithecidae infected by a HBV strain of human genotype
EP2552460A1 (en) 2010-03-29 2013-02-06 Universite De Strasbourg Polymers for delivering molecules of interest
EP2582387A2 (en) 2010-06-17 2013-04-24 The United States Of America As Represented By The Secretary, National Institutes Of Health Compositions and methods for treating inflammatory conditions
CA2802463C (en) 2010-06-22 2019-02-26 Dna Therapeutics Optimized in vivo delivery system with endosomolytic agents for nucleic acid conjugates
US9006417B2 (en) 2010-06-30 2015-04-14 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
US9956281B2 (en) 2011-05-04 2018-05-01 Streck, Inc. Inactivated virus compositions and methods of preparing such compositions
WO2013040552A2 (en) 2011-09-16 2013-03-21 Georgia Health Sciences University Methods of promoting immune tolerance
CA2856116A1 (en) 2011-11-17 2013-05-23 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Therapeutic rna switches compositions and methods of use
RS57066B1 (sr) 2011-11-24 2018-06-29 Genethon Sa industrijskim farmaceutskim primenama kompatibilan skalabilan proizvodni sistem lentiviralnog vektora
US9035039B2 (en) 2011-12-22 2015-05-19 Protiva Biotherapeutics, Inc. Compositions and methods for silencing SMAD4
BR112014029807A2 (pt) * 2012-06-08 2017-06-27 Ethris Gmbh administração pulmonar de rna mensageiro
CN103059295B (zh) * 2012-09-26 2016-01-13 上海交通大学 疏水修饰的聚乙烯亚胺及其作为蛋白质载体的用途
ES2919864T3 (es) 2012-10-05 2022-07-28 Biontech Delivery Tech Gmbh Derivados de poliamina hidroxilada como reactivos de transfección
CN112370532A (zh) 2012-10-08 2021-02-19 生物技术传送科技有限责任公司 作为转染试剂的羧化多胺衍生物
DE102012111891A1 (de) * 2012-12-06 2014-06-12 Eberhard Karls Universität Tübingen Medizinische Fakultät Verbesserung der Zielfindungskapazität von Stammzellen
ES2938048T3 (es) 2013-07-24 2023-04-04 Streck Llc Composiciones y procedimientos para estabilizar las células tumorales circulantes
US20160296632A1 (en) 2013-11-13 2016-10-13 Aequus Biopharma, Inc. Engineered glycoproteins and uses thereof
US10415037B2 (en) 2014-10-02 2019-09-17 Arbutus Biopharma Corporation Compositions and methods for silencing hepatitis B virus gene expression
EP3034539A1 (en) 2014-12-19 2016-06-22 Ethris GmbH Compositions for introducing nucleic acid into cells
US11168351B2 (en) 2015-03-05 2021-11-09 Streck, Inc. Stabilization of nucleic acids in urine
KR20180015145A (ko) 2015-05-05 2018-02-12 이섬 리서치 디벨러프먼트 컴파니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. 핵산-양이온성 중합체 조성물 및 그의 제조 및 사용 방법
US20180245074A1 (en) 2015-06-04 2018-08-30 Protiva Biotherapeutics, Inc. Treating hepatitis b virus infection using crispr
US20180208932A1 (en) 2015-07-29 2018-07-26 Arbutus Biopharma Corporation Compositions and methods for silencing hepatitis b virus gene expression
US20170145475A1 (en) 2015-11-20 2017-05-25 Streck, Inc. Single spin process for blood plasma separation and plasma composition including preservative
US10010627B2 (en) 2016-06-03 2018-07-03 International Business Machines Corporation Modified polycationic polymers
US11506655B2 (en) 2016-07-29 2022-11-22 Streck, Inc. Suspension composition for hematology analysis control
JP7078620B2 (ja) 2016-11-16 2022-05-31 イミュノミック セラピューティックス， インコーポレイテッド アレルギーの治療のための核酸
WO2018134310A1 (en) 2017-01-19 2018-07-26 Universiteit Gent Molecular adjuvants for enhanced cytosolic delivery of active agents
WO2018195527A1 (en) 2017-04-22 2018-10-25 Immunomic Therapeutics, Inc. Improved lamp constructs
KR20240027895A (ko) 2017-05-02 2024-03-04 이뮤노믹 쎄라퓨틱스, 인크. 암 항원을 포함하는 lamp (리소솜 연관 막 단백질) 구축물
JP2021523185A (ja) 2018-05-15 2021-09-02 イミュノミック セラピューティックス， インコーポレイテッドＩｍｍｕｎｏｍｉｃ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． アレルゲンを含む改善されたｌａｍｐ構築物
TW202043256A (zh) 2019-01-10 2020-12-01 美商健生生物科技公司 ***新抗原及其用途
AU2020366515A1 (en) 2019-10-18 2022-04-21 Immunomic Therapeutics, Inc. Improved lamp constructs comprising cancer antigens
WO2021099906A1 (en) 2019-11-18 2021-05-27 Janssen Biotech, Inc. Vaccines based on mutant calr and jak2 and their uses
US20230024133A1 (en) 2020-07-06 2023-01-26 Janssen Biotech, Inc. Prostate Neoantigens And Their Uses
US20230035403A1 (en) 2020-07-06 2023-02-02 Janssen Biotech, Inc. Method For Determining Responsiveness To Prostate Cancer Treatment
US20230029453A1 (en) 2020-07-06 2023-02-02 Janssen Biotech, Inc. Prostate Neoantigens And Their Uses
CN112237633B (zh) * 2020-10-22 2023-06-27 林君玉 一种pei/on复合物及其制备方法和用途
CN117098541A (zh) 2020-11-25 2023-11-21 阿卡格拉医药公司 用于递送核酸的脂质纳米粒及相关使用方法
GB202108176D0 (en) 2021-06-08 2021-07-21 Touchlight Ip Ltd Vector
AU2022289260A1 (en) 2021-06-08 2023-12-07 Touchlight IP Limited Lentiviral vector
WO2023201201A1 (en) 2022-04-10 2023-10-19 Immunomic Therapeutics, Inc. Bicistronic lamp constructs comprising immune response enhancing genes and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5286634A (en) * 1989-09-28 1994-02-15 Stadler Joan K Synergistic method for host cell transformation
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5283185A (en) * 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
AU3945493A (en) * 1992-04-06 1993-11-08 University Of Medicine And Dentistry Of New Jersey Paired-ion oligonucleotides and methods for preparing same
US6172208B1 (en) * 1992-07-06 2001-01-09 Genzyme Corporation Oligonucleotides modified with conjugate groups
US5334761A (en) * 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids

Also Published As

Publication number Publication date
CA2194797A1 (fr) 1996-02-01
NO970049L (no) 1997-01-07
FI970115A0 (fi) 1997-01-10
WO1996002655A1 (fr) 1996-02-01
ZA955849B (en) 1996-02-21
NO970049D0 (no) 1997-01-07
JP4275728B2 (ja) 2009-06-10
FI119738B (fi) 2009-02-27
PT770140E (pt) 2007-10-19
DE69535540T2 (de) 2008-06-19
IL114566A0 (en) 1995-11-27
KR970704889A (ko) 1997-09-06
DK0770140T3 (da) 2007-11-19
MX9700270A (es) 1997-05-31
NO323110B1 (no) 2007-01-02
ES2290952T3 (es) 2008-02-16
US6013240A (en) 2000-01-11
EP0770140A1 (fr) 1997-05-02
FR2722506B1 (fr) 1996-08-14
FR2722506A1 (fr) 1996-01-19
CA2194797C (fr) 2010-03-23
JPH10502918A (ja) 1998-03-17
AU2930795A (en) 1996-02-16
ATE367448T1 (de) 2007-08-15
IL114566A (en) 2005-08-31
DE69535540T9 (de) 2012-03-15
EP0770140B1 (fr) 2007-07-18
KR100424802B1 (ko) 2004-06-23
DE69535540D1 (de) 2007-08-30

Similar Documents

Publication Publication Date Title
FI970115A (fi) Nukeliinihappoja sisältävä valmiste, sen valmistus ja käytöt
FI962799A (fi) Nukleiinihappoja sisältävä valmiste, sen valmistus ja käyttö
FR2715847B1 (fr) Composition contenant des acides nucléiques, préparation et utilisations.
DE69829287D1 (de) Verbesserung der verabreichung der nukleinsäure in zellen der plurizellulären eukaryotischen organismen und kombination zur durchführung des verfahrens
FI973467A (fi) DNA-molekyylejä, valmistus ja käyttö geeniterapiassa
BG101103A (en) Mammalian telomerase
BR9810369A (pt) Processo de transferência de ácido nucleico para o interior de um ou mais músculos estriados, in vivo, composição, ácido mucleico e campo elétrico, e, produto de combinação
EP0957926A4 (en) OLIGONUCLEOTIDE COMPOSITION AND METHOD FOR REGULATING THE PROTEIN B7 EXPRESSION
DE69808274D1 (de) Kombinationsprodukt, enthaltend eine nukleinsäure und eine substanz, die die extrazellulärematrix desorganisiert, zur verwendung in gentherapie
EP1123414A4 (en) ANTISENSE MODULATION OF THE EXPRESSION OF INTEGRIN ALPHA 4
DE69228997T2 (de) Menschliche il-3-varianten
HUT77029A (hu) A GAP-protein SH3 doménjéhez kötődni képes peptidek, ezeket kódoló nukleotidszekvenciák és előállításuk és alkalmazásuk
BR9910787A (pt) Métodos e composições úteis para modulação deangiogênese usando tirosina cinase src
HK1002658A1 (en) Imidazopyridine-azolidinones their preparation and pharmaceutical use
ATE221895T1 (de) Chimäre oligonucleotide und ihre verwendung
BR9712210A (pt) Processos de preparação de uma composição para a transferência de ácidos nucléicos e para a transferência de ácido nucléico em células in vitro ou ex vivo, e, composição para a transferência de ácidos nucléicos.

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 119738

Country of ref document: FI

MA Patent expired